Tiago Torres, Paulo Varela, Pedro Mendes Bastos, Sofia Magina, Martinha Henrique, & Paulo Ferreira. (2024). Tildrakizumab for the treatment of moderate-to-severe psoriasis: A 52-week, real-world Portuguese multicentric study. BioExcel Publishing Ltd.
Chicago Style (17th ed.) CitationTiago Torres, Paulo Varela, Pedro Mendes Bastos, Sofia Magina, Martinha Henrique, and Paulo Ferreira. Tildrakizumab for the Treatment of Moderate-to-severe Psoriasis: A 52-week, Real-world Portuguese Multicentric Study. BioExcel Publishing Ltd, 2024.
MLA (9th ed.) CitationTiago Torres, et al. Tildrakizumab for the Treatment of Moderate-to-severe Psoriasis: A 52-week, Real-world Portuguese Multicentric Study. BioExcel Publishing Ltd, 2024.
Warning: These citations may not always be 100% accurate.